Лучшие больницы для «Cervical Cancer Treatment» в Хайдарабад, Индия

The cost of cervical cancer treatment varies significantly between India and the UAE based on the treatment modality, stage of disease, and the specific hospital chosen. In India, the total cost for surgical treatment (radical hysterectomy with lymph node dissection) typically ranges from USD 4,000 to USD 10,000, while a full course of concurrent chemoradiation—including external beam radiotherapy, brachytherapy, and weekly cisplatin chemotherapy—ranges from USD 5,000 to USD 15,000. Combined surgery plus adjuvant chemoradiation may cost USD 10,000–18,000. Immunotherapy courses (pembrolizumab) or advanced biologic agents (bevacizumab, tisotumab vedotin) add to costs based on the number of cycles required. In the UAE (Dubai or Abu Dhabi), the same treatment modalities cost approximately USD 10,000–40,000, with surgical procedures ranging from USD 10,000–20,000 and chemoradiation courses from USD 18,000–35,000. India is consistently 40–60% more affordable than the UAE. However, the UAE offers premium hospital infrastructure, luxury recovery environments, and ease of access for patients from the GCC, Africa, and Europe. Both destinations provide JCI-accredited oncology facilities with internationally trained specialists. GAF Healthcare provides transparent cost estimates inclusive of hospital fees, surgeon fees, standard medications, diagnostics, and accommodation for one attendant before you commit to travel.

The minimum required stay depends on the treatment modality. For patients undergoing radical hysterectomy (surgical treatment only) without complications, the hospital stay is typically 5–10 days, after which approximately 2–4 additional weeks of local recovery are recommended before a long-haul international flight is considered safe. The primary concerns before flying are: complete wound healing, restoration of bladder function (catheter removal and bladder training completed), normalisation of haematological parameters, and DVT risk reduction. Most surgical patients are cleared to fly at approximately 4–6 weeks post-operatively with prophylactic anticoagulation for the flight. For patients completing a full concurrent chemoradiation course (EBRT plus brachytherapy, total 6–7 weeks), the hospital/clinic-based treatment phase itself requires a stay of 6–7 weeks. After treatment completion, a further 1–2 weeks are recommended for acute toxicity resolution (haematological recovery, bowel and bladder symptom stabilisation) before long-haul travel. These patients should expect a total country stay of 7–9 weeks. Patients receiving immunotherapy or systemic therapy in cycles typically require 3-weekly visits for infusion and are managed on a cycle-by-cycle basis. GAF Healthcare provides a personalised fit-to-fly certificate and discharge planning document for every patient, coordinated with the treating oncologist.

Success rates for cervical cancer treatment are strongly stage-dependent and should be interpreted with reference to the specific FIGO stage, histological subtype, and treatment modality. At JCI-accredited high-volume cancer centres in India and the UAE partnered with GAF Healthcare, published and reported five-year survival rates are: Stage IA (micro-invasive): 95–98% with surgical treatment; Stage IB1–IB2: 85–92% with radical hysterectomy or definitive chemoradiation; Stage IIA: 75–85% with combined modality treatment; Stage IIB: 65–75% with concurrent chemoradiation; Stage IIIA–IIIB: 40–65% with concurrent chemoradiation and modern IMRT/IGABT brachytherapy; Stage IVA (localised pelvic metastasis): 15–30%; Stage IVB (distant metastasis): Median overall survival has improved to 17–24 months with the addition of pembrolizumab immunotherapy to platinum-based chemotherapy in PD-L1 positive patients (KEYNOTE-826 data). Local control rates for Stage IB–IIB cervical cancer treated with MRI-guided image-guided adaptive brachytherapy (IGABT) following IMRT reach 85–95% at three years, based on GEC-ESTRO EMBRACE study data replicated at leading centres. These figures are benchmarked against international datasets and reflect outcomes achievable at the specific high-volume oncology institutions in GAF Healthcare's partner network, which include institutions performing 200–500+ cervical cancer cases annually.